ABM Therapeutics has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for ABM-1310 to treat patients with glioblastoma (GBM) harbouring the BRAF V600 mutation.

A small-molecule BRAF inhibitor, ABM-1310 is an orally administered medicine with high BRAF mutation selectivity, blood-brain barrier permeability and water solubility.

The inhibitor is currently in Phase I trials at clinical sites in China and the US, targeting advanced solid tumours with the BRAF V600 mutation.

Interim results from the US Phase I trial showed that ABM-1310 exhibited promising anti-cancer activity and a good safety profile in patients with advanced solid tumours, including primary brain tumours such as GBM and other gliomas.

In China, a new Phase I clinical study focused specifically on GBM has recently commenced.

GBM is a hard-to-treat and extremely aggressive brain tumour. Its treatment remains a significant challenge owing to tumorigenesis complexities and resistance to the therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Traditional treatments such as surgical resection, radiation therapy and chemotherapy have limitations.

ABM Therapeutics, a clinical-stage biopharmaceutical company, focuses on small molecule research and the development of new medicines to treat cancer, specifically brain cancer and brain metastases from solid tumours.

ABM has been developing a pipeline for the construction of a brain medicine research and development platform known as BPKdd. The pipeline comprises several programmes at different stages of discovery and development.